IL17A and Sepsis: As a dual inhibitor of FAK and Pyk2, PF562271 improves survival rates in a mouse model of sepsis induced by cecal ligation and puncture (CLP); decreases the expression of pro-inflammatory factors such as TNF-α, IL-1β, IL-17, and IL-6; and alleviates inflammation as well as organ damage and dysfunction associated with sepsis [110].